Bioinformatics Advance Access originally published online on February 10, 2005
Bioinformatics 2005 21(10):2438-2446; doi:10.1093/bioinformatics/bti312
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimating cancer survival and clinical outcome based on genetic tumor progression scores
1Max-Planck Institute for Informatics Stuhlsatzenhausweg 85, D-66123 Saarbrücken, Germany
2Department of Urology, Heinrich-Heine University D-40225 Düsseldorf, Germany
3Department of Neuropathology, Charité, Humboldt University D-13353 Berlin, Germany
4Department of Urology and Pediatric Urology, University of the Saarland D-66421 Homburg/Saar, Germany
*To whom correspondence should be addressed.
Motivation: In cancer research, prediction of time to death or relapse is important for a meaningful tumor classification and selecting appropriate therapies. Survival prognosis is typically based on clinical and histological parameters. There is increasing interest in identifying genetic markers that better capture the status of a tumor in order to improve on existing predictions. The accumulation of genetic alterations during tumor progression can be used for the assessment of the genetic status of the tumor. For modeling dependences between the genetic events, evolutionary tree models have been applied.
Results: Mixture models of oncogenetic trees provide a probabilistic framework for the estimation of typical pathogenetic routes. From these models we derive a genetic progression score (GPS) that estimates the genetic status of a tumor. GPS is calculated for glioblastoma patients from loss of heterozygosity measurements and for prostate cancer patients from comparative genomic hybridization measurements. Cox proportional hazard models are then fitted to observed survival times of glioblastoma patients and to times until PSA relapse following radical prostatectomy of prostate cancer patients. It turns out that the genetically defined GPS is predictive even after adjustment for classical clinical markers and thus can be considered a medically relevant prognostic factor.
Availability: Mtreemix, a software package for estimating tree mixture models, is freely available for non-commercial users at http://mtreemix.bioinf.mpi-sb.mpg.de. The raw cancer datasets and R code for the analysis with Cox models are available upon request from the corresponding author.
Contact: rahnenfj{at}mpi-sb.mpg.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Gerstung, M. Baudis, H. Moch, and N. Beerenwinkel Quantifying cancer progression with conjunctive Bayesian networks Bioinformatics, November 1, 2009; 25(21): 2809 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beerenwinkel and S. Sullivant Markov models for accumulating mutations Biometrika, September 1, 2009; 96(3): 645 - 661. [Abstract] [PDF]
|
|
|
|
|
|
J. Bogojeska, A. Alexa, A. Altmann, T. Lengauer, and J. Rahnenfuhrer Rtreemix: an R package for estimating evolutionary pathways and genetic progression scores Bioinformatics, October 15, 2008; 24(20): 2391 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buness, R. Kuner, M. Ruschhaupt, A. Poustka, H. Sultmann, and A. Tresch Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer Bioinformatics, September 1, 2007; 23(17): 2273 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beerenwinkel and M. Drton A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data Biostat., January 1, 2007; 8(1): 53 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Jung, R. Kindich, J. Kamradt, M. Jung, M. Muller, W. A. Schulz, R. Engers, G. Unteregger, M. Stockle, R. Zimmermann, et al. Genomic and Expression Analysis of the 3q25-q26 Amplification Unit Reveals TLOC1/SEC62 as a Probable Target Gene in Prostate Cancer Mol. Cancer Res., March 1, 2006; 4(3): 169 - 176. [Abstract] [Full Text] [PDF]
|
|